Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director John Hassett was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • May 20
Lead Independent Director recently sold €542k worth of stock On the 12th of May, Daniel Croteau sold around 3k shares on-market at roughly €189 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.4m more than they bought in the last 12 months. Announcement • May 04
UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026 UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026. Announcement • May 01
UFP Technologies, Inc. to Report Q1, 2026 Results on May 04, 2026 UFP Technologies, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 04, 2026 Announcement • Feb 20
UFP Technologies, Inc. to Report Q4, 2025 Results on Feb 24, 2026 UFP Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026 Announcement • Oct 29
UFP Technologies, Inc. to Report Q3, 2025 Results on Nov 03, 2025 UFP Technologies, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025 Announcement • Jul 30
UFP Technologies, Inc. to Report Q2, 2025 Results on Aug 04, 2025 UFP Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025 Announcement • Jul 17
UFP Technologies, Inc. (NasdaqCM:UFPT) acquired Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million. UFP Technologies, Inc. (NasdaqCM:UFPT) entered into securities purchase agreement to acquire Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million on July 7, 2025. A cash consideration of $4.5 million will be paid by UFP Technologies, Inc. towards common equity of Techno Plastics Industries, Inc. The transaction were financed with available cash and borrowings under UFP’s existing credit facility.
For the period ending December 31, 2024, Techno Plastics Industries, Inc. reported total revenue of approximately $10 million and EBITDA of $1 million.
UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Techno Plastics Industries, Inc. from a group of shareholders on July 17, 2025. Announcement • May 01
UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025 UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025. Announcement • Apr 30
UFP Technologies, Inc. to Report Q1, 2025 Results on May 06, 2025 UFP Technologies, Inc. announced that they will report Q1, 2025 results Pre-Market on May 06, 2025 Announcement • Feb 19
UFP Technologies, Inc. to Report Q4, 2024 Results on Feb 25, 2025 UFP Technologies, Inc. announced that they will report Q4, 2024 results on Feb 25, 2025 Recent Insider Transactions • Nov 14
CEO & Chairman recently sold €8.3m worth of stock On the 11th of November, R. Bailly sold around 25k shares on-market at roughly €327 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €13m. R. has been a net seller over the last 12 months, reducing personal holdings by €49m. Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to €321, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 435% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €144 per share. Reported Earnings • Nov 05
Third quarter 2024 earnings released: EPS: US$2.13 (vs US$1.53 in 3Q 2023) Third quarter 2024 results: EPS: US$2.13 (up from US$1.53 in 3Q 2023). Revenue: US$145.2m (up 44% from 3Q 2023). Net income: US$16.4m (up 40% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 27
UFP Technologies, Inc. (NasdaqCM:UFPT) acquired AQF Ltd for €43 million. UFP Technologies, Inc. (NasdaqCM:UFPT) entered into a share purchase agreement to acquire AQF Ltd for €43 million on August 23, 2024. The shares were acquired for an aggregate purchase price of €43.0 million in cash. The aggregate purchase price at closing was approximately 12.3 times AQF Medical’s adjusted net income before interest, taxes, depreciation and amortization for the 12-month period ended June 30, 2024.
UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of AQF Ltd on August 26, 2024. Recent Insider Transactions • Aug 08
CFO, Senior VP & Treasurer recently sold €3.6m worth of stock On the 6th of August, Ronald Lataille sold around 13k shares on-market at roughly €278 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ronald has been a net seller over the last 12 months, reducing personal holdings by €3.7m. Reported Earnings • Aug 01
Second quarter 2024 earnings released: EPS: US$1.77 (vs US$1.56 in 2Q 2023) Second quarter 2024 results: EPS: US$1.77 (up from US$1.56 in 2Q 2023). Revenue: US$110.2m (up 10% from 2Q 2023). Net income: US$13.6m (up 14% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 73% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 02
First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.28 in 1Q 2023) First quarter 2024 results: EPS: US$1.66 (up from US$1.28 in 1Q 2023). Revenue: US$105.0m (up 7.4% from 1Q 2023). Net income: US$12.7m (up 30% from 1Q 2023). Profit margin: 12% (up from 10.0% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 29
UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024 UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect the seven directors identified as standing for election in the accompanying proxy statement, each to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected; to vote on a non binding advisory resolution to approve the compensation of named executive officers; to ratify the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ended December 31, 2024; and to transact such other business as may properly come before the 2024 Annual Meeting of Stockholders, and at any adjournment or postponement thereof. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €206, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total returns to shareholders of 390% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €294 per share. Recent Insider Transactions • Mar 03
CEO & Chairman recently sold €5.2m worth of stock On the 23rd of February, R. Bailly sold around 27k shares on-market at roughly €194 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €19m. Reported Earnings • Feb 22
Full year 2023 earnings released: EPS: US$5.89 (vs US$5.53 in FY 2022) Full year 2023 results: EPS: US$5.89 (up from US$5.53 in FY 2022). Revenue: US$400.1m (up 13% from FY 2022). Net income: US$44.9m (up 7.5% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Announcement • Feb 06
UFP Technologies, Inc. Announces Executive Changes UFP Technologies, Inc. announced the appointment of Mitchell Rock as President of the Company. Rock has been serving as President of the Company’s MedTech business. R. Jeffrey Bailly will continue in his capacity as Chairman and Chief Executive Officer. Recent Insider Transactions • Dec 18
Chairman of the Board of Directors recently sold €3.3m worth of stock On the 14th of December, R. Bailly sold around 20k shares on-market at roughly €164 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €11m. Recent Insider Transactions • Dec 06
Chairman of the Board of Directors recently sold €1.2m worth of stock On the 30th of November, R. Bailly sold around 7k shares on-market at roughly €158 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.9m. R. has been a net seller over the last 12 months, reducing personal holdings by €7.3m. Recent Insider Transactions • Nov 27
Chairman of the Board of Directors recently sold €208k worth of stock On the 21st of November, R. Bailly sold around 1k shares on-market at roughly €160 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.7m. R. has been a net seller over the last 12 months, reducing personal holdings by €3.2m. Reported Earnings • Nov 02
Third quarter 2023 earnings released: EPS: US$1.53 (vs US$2.58 in 3Q 2022) Third quarter 2023 results: EPS: US$1.53 (down from US$2.58 in 3Q 2022). Revenue: US$100.8m (up 3.9% from 3Q 2022). Net income: US$11.7m (down 40% from 3Q 2022). Profit margin: 12% (down from 20% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Recent Insider Transactions • Sep 03
Chairman of the Board of Directors recently sold €2.7m worth of stock On the 31st of August, R. Bailly sold around 17k shares on-market at roughly €163 per share. This transaction amounted to 4.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €12m. Reported Earnings • Aug 02
Second quarter 2023 earnings released: EPS: US$1.56 (vs US$1.18 in 2Q 2022) Second quarter 2023 results: EPS: US$1.56 (up from US$1.18 in 2Q 2022). Revenue: US$100.0m (up 6.0% from 2Q 2022). Net income: US$11.9m (up 33% from 2Q 2022). Profit margin: 12% (up from 9.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Recent Insider Transactions • May 10
Independent Director recently sold €3.4m worth of stock On the 8th of May, Thomas Oberdorf sold around 27k shares on-market at roughly €129 per share. This transaction amounted to 91% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €16m more than they bought in the last 12 months. Board Change • Apr 29
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Cynthia Feldmann was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €120, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total returns to shareholders of 102% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €85.63 per share. Reported Earnings • Mar 12
Full year 2022 earnings released: EPS: US$5.53 (vs US$2.11 in FY 2021) Full year 2022 results: EPS: US$5.53 (up from US$2.11 in FY 2021). Revenue: US$353.8m (up 72% from FY 2021). Net income: US$41.8m (up 163% from FY 2021). Profit margin: 12% (up from 7.7% in FY 2021). Revenue is forecast to grow 4.1% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. 
